Yarrow Bioscience Inc
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Yarrow Bioscience, Inc. operates as a biopharmaceutical company focused on developing and commercializing innovative therapies in oncology and related diseases. The company pursues a portfolio of drug candidates and platform technologies designed to advance cancer treatment, with an emphasis on targeted, patient-centric approaches and companion diagnostic strategies. Main products and services - Therapeutic candidates: development of targeted oncology therapies through small molecules, biologics, and antibody-drug conjugates designed to improve efficacy and safety profiles in specific cancer indications; advancement of combination regimens with existing treatments where applicable - Platform technologies: research and development platforms that enable precision medicine, including biomarker-driven patient selection, companion diagnostic integration, and streamlined translational science to support clinical development - Clinical development services: nonclinical and preclinical collaboration for candidate evaluation, translational research, pharmacology/toxicity assessment, and early-stage clinical trial design - Regulatory and filing support: preparation and submission of regulatory documentation, engagement with health authorities, and strategy for accelerated or conditional approvals where feasible - Manufacturing and supply chain planning: early-stage process development support, scale-up planning, and potential manufacturing partnerships to support clinical and later-stage production - Commercialization planning services: market access analyses, competitive positioning, pricing and reimbursement strategy considerations, and lifecycle management insights for future product launches Latest major company changes - Strategic partnerships: enters collaborations with pharmaceutical and biotechnology entities to co-develop or license oncology programs, including optional or milestone-based agreements intended to broaden the pipeline and accelerate clinical development - Funding and capitalization: secures financing rounds and strategic investments to support ongoing research programs, clinical trials, and platform expansion - Product and platform advancements: advances pipeline through initiation of new clinical trials, expansion of platform capabilities, and integration of biomarker-driven approaches into trial design - Corporate actions: organizational refinements or restructurings as the company scales its R&D and operations to support an expanded clinical portfolio - Geographic and operational expansion: broadens operational footprint to support multicenter clinical trials and potential regional manufacturing or partner arrangements Additional context - Industry and segments: biopharmaceuticals focused on oncology, precision medicine, and biomarker-driven therapies - Target markets: global cancer care providers, academic medical centers, contract research and manufacturing organizations, and payer landscapes in major markets - Geographic operations: headquartered in the United States with research and development activities potentially spanning multiple sites; geographic reach extends to collaboration partners and trial sites internationally - Founding year and headquarters: established in the early 2020s; headquarters located in the United States - Subsidiaries/parent relationships: operates as an independent publicly traded company with potential subsidiary arrangements tied to regional operations or development programs - Other notable considerations: maintains a focus on translating laboratory discoveries into clinically meaningful oncology therapies, with an emphasis on biomarker-informed patient selection and precision medicine approaches
Company News
Contrasting Yarrow Bioscience (NASDAQ:YARW) and Atara Biotherapeutics (NASDAQ:ATRA)
Yarrow Bioscience Announces Closing of its $172.5 Million Underwritten Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering
Yarrow Bioscience Announces Proposed Underwritten Public Offering
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update
Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves' Disease and Thyroid Eye Disease
VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience
VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience
VYNE Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Yarrow Bioscience
Short Interest in VYNE Therapeutics Inc. (NASDAQ:VYNE) Decreases By 35.7%
Contrasting Vivani Medical (NASDAQ:VANI) & VYNE Therapeutics (NASDAQ:VYNE)
VYNE Therapeutics Inc. (NASDAQ:VYNE) Short Interest Down 61.3% in February
Shareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of VYNE Therapeutics Inc. (NASDAQ: VYNE)
VYNE Therapeutics Inc. (VYNE) Yarrow Bioscience, Inc. - M&A Call Prepared Remarks Transcript
VYNE Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of VYNE Therapeutics Inc. is Fair to Shareholders
VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement
VYNE Therapeutics Inc. (VYNE) Reports Q3 Loss, Tops Revenue Estimates
VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update
Savara (NASDAQ:SVRA) vs. VYNE Therapeutics (NASDAQ:VYNE) Critical Comparison